UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038428
Receipt number R000043788
Scientific Title A Trial to Evaluate HbA1c Reduction after 8 Weeks Ingestion of Inulin-Containing Food - Double Blind Randomized Placebo-Controlled Parallel Group Study -
Date of disclosure of the study information 2019/10/29
Last modified on 2019/10/29 16:10:48

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Trial to Evaluate HbA1c Reduction after 8 Weeks Ingestion of Inulin-Containing Food
- Double Blind Randomized Placebo-Controlled Parallel Group Study -

Acronym

A Trial to Evaluate HbA1c Reduction after 8 Weeks Ingestion of Inulin-Containing Food

Scientific Title

A Trial to Evaluate HbA1c Reduction after 8 Weeks Ingestion of Inulin-Containing Food
- Double Blind Randomized Placebo-Controlled Parallel Group Study -

Scientific Title:Acronym

A Trial to Evaluate HbA1c Reduction after 8 Weeks Ingestion of Inulin-Containing Food

Region

Japan


Condition

Condition

Not applicable

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Objective is to evaluate the efficacy of ingestion of test food to HbA1c reduction.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Change in HbA1c from baseline value

Key secondary outcomes

HbA1c (measured), insulin (change and measured), insulin (change and measured), CPR(change and measured), HOMA-R, and intestinal flora (Bifidobacterium)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment

No need to know


Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Daily ingestion of inulin-containing food for 8 weeks.

Interventions/Control_2

Daily ingestion of placebo food for 8 weeks.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male

Key inclusion criteria

(1) Adult males from 20 to 64 years old at the time of giving consent.
(2) Individuals with HbA1c values from 5.6 to <6.5 % at the time of screening.
(3) Individuals who are available at every designated hospital visit.
(4)Individuals who agree to participate in this study and can put signature and date to informed consent form by themselves prior to the study.

Key exclusion criteria

(1)Individuals who have history of serious gastrointestinal disease, liver disease, kidney disease, cardiovascular disease, blood disease, endocrine system disease, or malignant neoplasm, or individuals who are suspected to have these diseases.
(2) Individuals currently taking oral medication for internal diseases or receiving medical treatment.
(3) Individuals planning to take medicine or to receive medical treatment during in this study.
(4) Individuals planning to continuously take health food product or a supplement that indicates reduction of blood glucose and/or diabetes prevention during this study.
(5) Individuals who have possibility of changing a lifestyle (i.e. night work, long travel or transfer)
(6) Individuals with excessive alcohol drinking or heavy smoking
(7) Individuals who may have allergies to Asteraceae plants in relation to the test food.
(8) Individuals currently participating or planning to participate in any other clinical studies.
(9) Individuals judged as inappropriate for the trial by the principal investigator.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name Kazuhiko
Middle name
Last name Takano

Organization

Medical Corporation Hokubukai Utsukushigaoka Hospital

Division name

Clinical Pharmacology Center

Zip code

004-0839

Address

61-1, Sinei, Kiyota-ku, Sapporo, Hokkaido, Japan

TEL

0118820111

Email

takano@ughp-cpc.jp


Public contact

Name of contact person

1st name Takuya
Middle name
Last name Matsuda

Organization

Medical Corporation Hokubukai Utsukushigaoka Hospital

Division name

Clinical Pharmacology Center

Zip code

004-0839

Address

61-1, Sinei, Kiyota-ku, Sapporo, Hokkaido, Japan

TEL

0118820111

Homepage URL


Email

matsuda@ughp-cpc.jp


Sponsor or person

Institute

Medical Corporation Hokubukai Utsukushigaoka Hospital

Institute

Department

Personal name



Funding Source

Organization

NIHON TOUNYOU SYOKKEN CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Medical Corporation Hokubukai Utsukushigaoka Hospital institutional review board

Address

61-1, Sinei, Kiyota-ku, Sapporo, Hokkaido, Japan

Tel

0118820111

Email

matsuda@ughp-cpc.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人北武会 美しが丘病院(北海道)


Other administrative information

Date of disclosure of the study information

2019 Year 10 Month 29 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

20

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2019 Year 09 Month 30 Day

Date of IRB

2019 Year 10 Month 07 Day

Anticipated trial start date

2019 Year 10 Month 30 Day

Last follow-up date

2019 Year 12 Month 25 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 10 Month 29 Day

Last modified on

2019 Year 10 Month 29 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043788


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name